Squats And Planks For BP Lowering; DCBs Compared Head To Head; GLP-1s For HFpEF?

TL;DR

Prime Big Deal Days · Oct 6–7Offer from Amazon

Get workout gear delivered free — and shop member deals

• Fast, free delivery on millions of items
• Access to Prime Big Deal Days deals on October 6–7
• Prime Video, Amazon Music and more included

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

A MedPage Today roundup published October 6, 2026, highlighted research on isometric exercise, drug-coated balloons for peripheral artery disease and semaglutide in obesity-associated HFpEF. The exercise finding came from a randomized study, the balloon comparison was small and showed no material difference in 12-month patency or repeat procedures, and the semaglutide result was preclinical—not evidence of benefit in patients.

A cardiovascular research roundup published October 6 highlighted three developments: a randomized study of isometric exercise for short-term blood pressure reduction, a small comparison of two drug-coated balloons for severe peripheral artery disease, and preclinical research suggesting semaglutide could be relevant to obesity-associated heart failure with preserved ejection fraction (HFpEF). The findings are at different stages of evidence: the HFpEF result came from a preclinical study, while the balloon trial found no material difference in key 12-month outcomes.

The exercise study, published in BMJ Open Sport & Exercise Medicine, found that isometric training—including exercises such as squats and planks—was best performed three times a week for short-term blood pressure-lowering benefits. The roundup did not provide the size of the blood pressure change, the length of the study, or details about participants, so the finding should not be read as a prescription for every patient or as evidence of lasting effects.

A small trial published in the Journal of the American Heart Association compared sirolimus- and paclitaxel-eluting drug-coated balloons (DCBs) used to treat severe peripheral artery disease. Sirolimus was better at restoring endothelial function, but the study reported no material change in 12-month patency or target lesion revascularization rates. These measures address whether the treated vessel remained open and whether patients needed another procedure on the target lesion.

Separately, a study in the European Heart Journal described semaglutide—marketed as Ozempic and Wegovy—as a plausible therapy for obesity-associated cardiometabolic HFpEF. That conclusion came from preclinical research, not a reported clinical trial showing that semaglutide improves outcomes in people with HFpEF. The roundup also summarized other cardiovascular developments, including an American College of Cardiology statement on diet and a meta-analysis of left atrial appendage closure, but the three findings above carry distinct levels of evidence and clinical readiness.

Different Evidence, Different Implications

The three reports matter because they address common cardiovascular concerns while showing why study design and endpoints matter. Blood pressure is a modifiable risk factor, and a practical exercise finding may interest patients and clinicians. But the report only describes short-term benefit and does not supply enough detail to establish the size or durability of any change.

The balloon comparison speaks to treatment choices for severe peripheral artery disease. The better endothelial-function result with sirolimus is a biological measure, while vessel patency and repeat treatment are more direct clinical outcomes. Because the latter did not materially differ at 12 months, the reported result does not establish that one balloon provides better clinical performance overall.

The semaglutide finding is relevant amid interest in treatments that address obesity and heart disease, but it is still an early signal. Preclinical evidence cannot establish patient benefit; clinical studies would be needed to test safety, effectiveness and appropriate use in HFpEF. Treating it as proven therapy would go beyond what the roundup reports.

Three Studies at Different Stages

The roundup was a brief survey of recent cardiovascular research, not a single trial or unified clinical recommendation. Its items ranged from a randomized exercise study to a small device comparison and laboratory-stage work. Those distinctions are important: a randomized study can test an intervention in people, a small trial may leave meaningful uncertainty about outcomes, and preclinical research generally supplies a rationale for further investigation rather than a basis for routine treatment.

In the DCB study, the comparison involved balloons coated with different medicines, sirolimus and paclitaxel. The reported finding separated an improvement in endothelial function from the clinical measures of patency and repeat intervention. In the HFpEF item, the roundup described semaglutide as plausible based on preclinical findings; it did not report that a human trial had confirmed benefit. The exercise report, meanwhile, specified a frequency of three sessions per week but omitted other details needed to interpret the result for individual patients.

“Isometric exercise training — such as squats and plank exercises — was best done three times a week for short-term blood pressure-lowering benefits.”

— MedPage Today roundup, summarizing the randomized exercise study

Limits of the Reported Findings

The source summary does not give the exercise study’s participant count, blood pressure effect size, follow-up duration or longer-term results. It also does not specify the size or detailed design of the DCB trial. The absence of those details makes it difficult to judge how broadly its findings apply, including whether the endothelial-function difference has consequences beyond the reported measure.

For semaglutide, the key uncertainty is whether the preclinical findings translate into meaningful benefits and acceptable risks in people with HFpEF. The roundup does not identify a human trial or provide clinical outcome data for this use. It also does not say when such evidence might become available. The findings therefore should not be treated as a change to established care based on this report alone.

Clinical Evidence Still Needed

Further research would need to clarify how long any blood pressure reduction from isometric training lasts, how large it is, and which people are most likely to benefit. Patients considering a new exercise routine should discuss it with a health professional, particularly if they have cardiovascular conditions or other health concerns.

For DCBs, larger or longer studies could test whether the endothelial-function finding translates into differences in vessel durability, repeat procedures or other patient outcomes. For semaglutide in HFpEF, the next meaningful step would be clinical research in people with the condition; the roundup gives no trial timetable or confirmed next milestone. Until such results are reported, the HFpEF claim remains a preclinical possibility rather than demonstrated treatment benefit.

Key Questions

What did the exercise study report?

The randomized study reported that isometric exercise, including squats and planks, was best done three times weekly for short-term blood pressure-lowering benefits. The roundup did not provide the effect size or study duration.

Did sirolimus-coated balloons outperform paclitaxel-coated balloons?

In the small trial, sirolimus was better for restoring endothelial function. The report said there was no material difference in patency or target lesion revascularization at 12 months, so it did not establish an overall clinical advantage.

Is semaglutide proven to treat HFpEF?

No. The reported finding was preclinical and described semaglutide as a plausible therapy for obesity-associated HFpEF. The roundup did not report clinical trial evidence proving benefit in people with the condition.

Can patients use these findings to change their care?

The roundup does not provide enough information to guide an individual treatment decision. Patients should discuss blood pressure exercise plans and medication questions with a clinician rather than treating early or limited findings as personal medical advice.

Source: rss